Synthetic peptides containing ITIM-like sequences of IREM-1 (CD300F) differentially regulate MyD88 and TRIF-mediated TLR signalling through activation of SHP and/or PI3K

Clinical and Experimental Immunology

Volumn 167, Issue 3, 2012, Pages 438-446

  Lee, S M ^a   Suk, K ^b   Lee, W H ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Inflammation; IREM 1; ITIM; Macrophage; TLR signalling

Indexed keywords

GELATINASE B; HYBRID PROTEIN; IMMUNE RECEPTOR EXPRESSED ON MYELOID CELL 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE SHP; RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOREGULATION; INTERNALIZATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; WESTERN BLOTTING;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; AMINO ACID SEQUENCE; CELL LINE; HUMANS; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 9; MOLECULAR SEQUENCE DATA; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, IMMUNOLOGIC; SH2 DOMAIN-CONTAINING PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TOLL-LIKE RECEPTORS;

EID: 84863049411     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04528.x     Document Type: Article

References (41)

1. Alvarez-Errico D, Aguilar H, Kitzig F, Brckalo T, Sayos J, Lopez-Botet M. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. Eur J Immunol 2004; 34:3690-701.
2. Sui L, Li N, Liu Q etal. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochem Biophys Res Commun 2004; 319:920-8.
3. Chung DH, Humphrey MB, Nakamura MC, Ginzinger DG, Seaman WE, Daws MR. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol 2003; 171:6541-8.
4. Shibuya A, Nakahashi-Oda C, Tahara-Hanaoka S. Regulation of immune responses by the activating and inhibitory myeloid-associate immunoglobuline-like receptors (MAIR) (CD300). Immune Netw 2009; 9:41-5.
5. Xi H, Katschke KJ Jr, Helmy KY etal. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med 2010; 207:7-16, S1-5.
6. Izawa K, Kitaura J, Yamanishi Y etal. An activating and inhibitory signal from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments lipopolysaccharide response through association with FcRgamma in mast cells. J Immunol 2009; 183:925-36.
7. Lee SM, Nam YP, Suk K, Lee WH. IREM-1 inhibits BAFF-mediated inflammatory regulation of THP-1 cells through modulation of the activities of ERK. Clin Exp Immunol 2010; 161:504-11.
8. Lee SM, Kim EJ, Suk K, Lee WH. Stimulation of FasL induces production of pro-inflammatory mediators through activation of mitogen activated protein kinases and nuclear factor-kappaB in THP-1 cells. Inflammation 2012 (in press).
9. Lee SM, Kim EJ, Suk K, Lee WH. CD300F blocks both MyD88 and TRIF-mediated TLR signaling through activation of SHP-1. J Immunol 2011; 186:6296-303.
10. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
11. Nasu K, Narahara H. Pattern recognition via the Toll-like receptor system in the human female genital tract. Mediators Inflamm 2010. doi: 10.1155/2010/976024.
12. Fitzgerald KA, Palsson-McDermott EM, Bowie AG etal. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78-83.
13. Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem 2009; 284:24192-203.
14. Zhang FX, Kirschning CJ, Mancinelli R etal. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274:7611-14.
15. Wietek C, Miggin SM, Jefferies CA, O'Neill LA. Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa. J Biol Chem 2003; 278:50923-31.
16. Chang M, Jin W, Sun SC. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol 2009; 10:1089-95.
17. Meylan E, Burns K, Hofmann K etal. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004; 5:503-7.
18. Lee WH, Kim SH, Lee Y etal. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001; 21:2004-10.
19. Harada Y, Tokushima M, Matsumoto Y etal. Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo. J Immunol 2001; 166:3797-803.
20. Alvarez-Errico D, Sayos J, Lopez-Botet M. The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. J Immunol 2007; 178:808-16.
21. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007; 22:1251-67.
22. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 2009; 228:342-59.
23. Arabaci G, Guo XC, Beebe KD, Coggeshall KM, Pei D. α-Haloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J Am Chem Soc 1999; 121:5085-6.
24. Lorenz U, Ravichandran KS, Pei D, Walsh CT, Burakoff SJ, Neel BG. Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase SH-PTP1 in murine T cells. Mol Cell Biol 1994; 14:1824-34.
25. Uchida T, Matozaki T, Noguchi T etal. Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains. J Biol Chem 1994; 269:12220-8.
26. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol 2010; 346:31-56.
27. Carpenter CL, Auger KR, Chanudhuri M etal. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993; 268:9478-83.
28. Street A, Macdonald A, Crowder K, Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 2004; 279:12232-41.
29. Hardin AO, Meals EA, Yi T, Knapp KM, English BK. SHP-1 inhibits LPS-mediated TNF and iNOS production in murine macrophages. Biochem Biophys Res Commun 2006; 342:547-55.
30. Christophi GP, Hudson CA, Panos M, Gruber RC, Massa PT. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol 2009; 83:522-39.
31. Christophi GP, Massa PT. Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1. Viral Immunol 2009; 22:371-87.
32. Christophi GP, Panos M, Hudson CA etal. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Investig 2009; 89:742-59.
33. An H, Hou J, Zhou J etal. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 2008; 9:542-50.
34. Strassheim D, Asehnoune K, Park JS etal. Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J Immunol 2004; 172:5727-33.
35. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277:32124-32.
36. Pahan K, Raymond JR, Singh I. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J Biol Chem 1999; 274:7528-36.
37. Li X, Tupper JC, Bannerman DD, Winn RK, Rhodes CJ, Harlan JM. Phosphoinositide 3 kinase mediates Toll-like receptor 4-induced activation of NF-kappa B in endothelial cells. Infect Immun 2003; 71:4414-20.
38. Diaz-Guerra MJ, Castrillo A, Martin-Sanz P, Bosca L. Negative regulation by phosphatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J Immunol 1999; 162:6184-90.
39. Aksoy E, Vanden Berghe W, Detienne S etal. Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4. Eur J Immunol 2005; 35:2200-9.
40. Wu Y, Zhu X, Li N etal. CMRF-35-like molecule 3 preferentially promotes TLR9-triggered proinflammatory cytokine production in macrophages by enhancing TNF receptor-associated Factor 6 ubiquitination. J Immunol 2011; 187:4881-9.
41. Barrow AD, Trowsdale J. You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 2006; 36:1646-53.